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Abstract
Women who undergo percutaneous coronary intervention (PCI) are at higher risk of adverse outcomes compared to men but it is unknown whether sex affects early unplanned rehospitalization.  We analyzed 832,753 patients who underwent PCI between 2013 and 2014 in the Nationwide Readmissions Database. We compared sex difference in incidences, predictors, causes and cost of unplanned 30-day readmissions and examined the effect of comorbidity.  A total of 832,753 men and women who survived the index PCI and were not admitted for a planned readmission were included in the analysis.  Overall, 9.4% of patients had an unplanned readmission within 30 days.  30-day readmission rates were higher in women compared to men (11.5% vs 8.4%, p<0.001) even after multivariate adjustment (OR 1.19, 1.16-1.22, p<0.001) although women had significantly lower costs associated with the  readmission  ($11,927 vs $12,758, p<0.001). The cause of readmission for women and men were similar and the majority were due to non-cardiac causes 58% vs 55%, the most common of which were non-specific chest pain, gastrointestinal disease and infections. In contrast for cardiac readmissions, women are more likely to be readmitted with heart failure (29.64% vs 22.34%) while men are more likely to be readmitted with coronary artery disease including angina (33.47% vs 28.54%). In conclusion, sex disparities exist in rates of unplanned rehospitalization following PCI where more than 1 in 10 women who undergo PCI are readmitted within 30 days. Whilst sex differences were not observed for causes of non cardiac readmissions important differences were observed for cardiovascular causes.






Percutaneous coronary intervention (PCI) is one of the most commonly performed procedures in the United States1 and unplanned readmissions after PCI are a growing area of interest, that are not well understood.  Readmissions are not only a burden to patients and healthcare services but also serve as an indicator of quality of care which can incur financial penalties for hospitals with unplanned readmissions considered an adverse outcome for patients.2 Hospital readmissions may act as a surrogate for the quality of care received from the initial in-hospital episode.  They may result from actions taken or omitted during the initial hospital stay or be a consequence of incomplete treatment or failure of services to coordinate post-discharge care. Women undergoing PCI are older, have a greater burden of comorbid conditions, more complex disease,3,4 and are more likely to experience peri-procedural complications following PCI,5,6 that are important factors that may contribute to differences in both, the rates and causes of unplanned readmissions across sexes. Previous work on unplanned readmissions post PCI has not considered whether sex disparities exist in either the rates or causes of readmission.7,8  The objective of the current study is to evaluate the incidence, predictors and outcomes in unplanned 30-day readmissions following PCI, to assess for differences across sex, and to determine whether there are sex specific differences in the causes of unplanned readmissions.

Methods
The Nationwide Readmissions Database (NRD) provides a nationally representative sample of all-age, all-payer discharges from US non-federal hospitals that is produced by the Healthcare Cost and Utilization Project of the Agency for Healthcare Research and Quality.9 This database is constructed from the discharge-level data of hospitalizations from 21 geographically-dispersed participating states which represents 49.3% of the total US population and 49.1% of all US hospitalizations.10 Readmissions are determined through the de-identified unique patient linkage number assigned to each patient, which allows tracking of patients across hospitals within a state during a calendar year.  
We included men and women who underwent PCI with discharge dates between 2013 to 2014 with 30-day follow up.  Individual patients in the NRD dataset are assigned up to 15 procedure codes for each admission to hospital.  We defined patients with PCI with procedure code 0066 (PTCA OR CORONARY ATHER), 3606 (INSERT CORON ART STENT) and 3607 (INSERT DRUG ELUTING CRNRY AR). We excluded patients who died in-hospital during the index PCI and those who were readmitted electively within 30 days as these were considered to be planned readmissions.  We further excluded patients that were discharged in December because they would not have 30 days follow up data for readmissions during the same calendar year.
The primary outcome was the rate of unplanned readmission within 30 days of hospitalization with PCI.  Costs were determined by multiplying the hospital charges with AHRQ’s all-payer cost-to-charge ratios for each hospital. 
We used International Statistical Classification of Diseases and Related Health Problems (ICD) 9 codes to define several variables including smoking status (V1582 3051), dyslipidemia (2720-2724), coronary artery disease (41400-41407), previous myocardial infarction (412), previous PCI (V4582), previous CABG (V4581), previous stroke or TIA (V1254 438*), atrial fibrillation (42731), dementia (290* 2941* s942* 3310-3312, 33182, 797) and receipt of circulatory support (3761 3768 3965).  Elixhauser comorbidities were defined in the dataset which were also used including alcohol, chronic lung disease, heart failure, diabetes, valvular heart disease, peptic ulcer disease, hypertension, renal failure, obesity, cancer, fluid and electrolyte disorders, depression, peripheral vascular disease, hypothyroidism, liver disease, anemia and coagulopathy.  The paralysis variable from the Elixhauser comorbidities was used as a surrogate for hemiplegia and connective tissue disease and leukemia where defined by Clinical Classification Software (CCS) codes 210, 211 & 39 respectively.  Combining these variables enable determination of the Charlson comorbidity index.  The Charlson co-morbidity index is a measure of co-morbidity burden and provides a means of quantifying the prognostic impact of 22 comorbid conditions on the basis of their number and their individual prognostic impact by means of a score that was developed as a prognostic indicator for patients with a variety of medical conditions.11 Diagnosis of acute myocardial infarction was defined by primary diagnosis code of 410x and 4111.  The causes of readmission were determined by the first diagnosis based on Clinical Classification Software codes, which are presented in detail in Supplementary Table 1.
Statistical analysis was performed on Stata 14.0 (College Station, TX).  Descriptive statistics are presented according to sex and readmission for all included variables.  The t-test was used to compare continuous variables while the Chi2 test was used to compare categorical variables according to readmission status.  Multiple logistic regression, adjusted for age, elective admission, weekend admission, diagnosis of acute myocardial infarction, payer, income, smoking, alcohol misuse, dyslipidemia, hypertension, diabetes, obesity, heart failure, coronary artery disease, previous myocardial infarction, previous PCI, previous CABG, valvular heart disease, atrial fibrillation, previous stroke/transient ischemic attack (TIA), peripheral vascular disease, pulmonary circulatory disorder, peptic ulcer disease, chronic lung disease, renal failure, liver disease, hypothyroidism, fluid and electrolyte disorders, anemia, cancer, depression, dementia, bed size, urban location, teaching hospital, multivessel disease, bifurcation disease, circulatory support, vasopressor use, intra-aortic balloon pump use, fractional fluid reserve use, intravascular ultrasound, drug eluting stent, in-hospital complete heart block, stroke/TIA, cardiogenic shock, cardiac arrest, acute kidney injury, major bleeding, blood transfusion, vascular complication, emergency CABG, length of stay and discharge destination, was used to identify independent predictors of 30-day readmissions after PCI for women and men.  The mean cost of index admission for PCI and the total costs associated with readmissions was computed and shown graphically.  The causes of readmission within 30 days are presented in figure and table format for non-cardiac and cardiac causes for readmissions.  A flow diagram was used to describe patient outcomes for both admissions and readmissions.

Results
A total of 832,753 men and women survived the index PCI and were included in this analysis (Figure 1). Of these, 9.4% (n=77,946) had an unplanned readmission within 30 days and 3.0% (n=2,307) died during the readmission episode.  
The characteristics of men and women at the index PCI is shown in Supplementary Table 2.  Women were significantly older than men (67.5 vs 63.5 years, p<0.001) and were more likely to receive Medicare and Medicaid whilst men were more likely to have private healthcare or be uninsured.  Women also had significantly lower income compared to men (p<0.001).  Women had more comorbidities compared with men.  Women were more likely to have diabetes (42.9% vs 35.2%, p<0.001), obesity (20.9% vs 15.8%, p<0.001), chronic lung disease (22.2% vs 15.3%, p<0.001), hypothyroidism (17.7% vs 6.0%, p<0.001), anemia (16.3% vs 9.1%, p<0.001) and depression (10.9% vs 5.3%, p<0.001). Comorbidity burden was also greater in women compared to men as defined both by Charlson comorbidity index (1.5±1.5 vs 1.3±1.5, p<0.001) and mean number of comorbidities (5.3±2.1 vs 4.8±2.1, p<0.001). Interestingly women had longer length of stays (4.4 days vs 3.7 days, p<0.001) and were less likely to be discharged home (80.2%) compared to men (88.8%); P<0.001. The 30-day readmission rates were greater in women compared to men (11.5% vs 8.4%, p<0.001).  The costs of index PCI and total costs was greater for women than for men (index admission for PCI $23,497 vs $23,307, p<0.001) but the cost of readmission was higher in men than women (readmission $12,758 vs $11,927, p<0.001) (Figure 2). Following adjustment for differences in clinical and procedural characteristics across sexes, female sex was independently associated with a 19% increased odds of readmission (OR 1.19, 95% CI 1.16-1.22, p<0.001).
Table 1 compares the characteristics of women and men according to readmission status. Readmitted patients were significantly older, regardless of sex, compared with those who were not readmitted [women (69.0 vs 67.3 years) and men (66.1 vs 63.3 years)] and the prevalence of comorbid conditions was significantly greater across both sexes for the cohort who had an unplanned readmission.  Several characteristics were significantly different for men but not women according to 30 day readmission status, including weekend admission (p=0.001 vs p=0.28), elective admission (p=0.009 vs p=0.59), heart failure (p<0.001 vs p=0.079), previous valve disease (p<0.001 vs p=0.15), atrial fibrillation (p<0.001 vs p=0.92), pulmonary circulatory disorder (p<0.001 vs p=0.27), chronic kidney disease (p<0.001 vs p=0.83), bifurcation disease (p<0.001 vs p=0.32), acute kidney injury (p<0.001 vs p=0.27) and major bleeding (p<0.001 vs p=0.32).
The independent predictors of 30-day unplanned readmissions are shown in Table 2.  A few key differences across sexes were observed. Diagnosis of acute myocardial infarction was associated with reduced odds of readmission (p<0.001) in men with no statistically significant associations observed in women (p=0.13).  Hypertension was not associated with increased odds of readmission for women (p=0.10 but it was for men (p=0.016).  Previous myocardial infarction increased the odds for readmission for men (p=0.004) but this was not significant for women (p=0.32).  Urban location was associated with increased odds of readmission in men (p=0.037) but not for women (p=0.12). In-hospital TIA/stroke was associated with reduced odds of readmission in women but not men (p=0.002 vs p=0.66). In general, comorbidities increased the odds of readmission for both women and men and a reduced length of index stay was associated with lower odds of readmission for both sexes. Furthermore, discharges to locations other than home (such as short term hospital transfer to another institution or a care home) were predictive of unplanned readmission. 
Table 3 provides an overview for the causes of readmission in women and men.  We observe that most readmissions were due to non-cardiac causes and men had a slightly higher readmission rate for non-cardiac causes compared to women 58% vs 55%.  The 10 most common causes for non-cardiac readmissions were similar across sexes but in terms of cardiac causes of readmission women were more likely to be admitted for heart failure while men were more likely to be readmitted for coronary heart disease including angina.

Discussion
Our analysis of over 800,000 PCI procedures suggests that 30 day unplanned readmission rates are significant across both sexes. We observe that women undergoing PCI are older, have more comorbidities and are more likely to experience peri-procedural complications than men. Even once these differences in baseline characteristics are adjusted for, women are 19% more likely to have an unplanned readmission compared to men at 30 days. We observed that the cost, causes and outcomes of the unplanned readmission are largely similar across sexes, although the commonest cardiac cause for readmission was heart failure in women and a diagnosis of coronary disease including angina in men.  Targeted interventions are needed to reduce readmissions particularly amongst women who represent a high-risk group of patients.
To the best of our knowledge, this is the first study to look specifically at sex disparities in early readmission after PCI and we provide several novel findings.  A previous analysis of the Partners Healthcare network with 9,288 PCIs in the United States suggests that nearly 1 in 10 of patients are readmitted within 30 days of discharge.7 Our analysis, which is more up-to-date (2013 to 2014 compared to 2007 to 2011), finds that women are more likely to be readmitted than men 11.5% vs 8.4%.  Even after adjustments for differences in important baseline variables and in-hospital outcomes, we observe that women are 19% more likely to have an unplanned early readmission post PCI. Furthermore, we show that the causes of non-cardiac readmissions are similar in men and women but for cardiac readmissions, women are more likely to be readmitted with heart failure (29.64% vs 22.34%) while men are more likely to be readmitted with coronary artery disease including angina (33.47% vs 28.54%).  
We demonstrate in the current study the importance of evaluating comorbidities in understanding sex related readmissions. Our analysis suggests that across both sexes, comorbidity burden represents one of the most important predictors of unplanned hospitalization. While individual cardiovascular comorbidities have been evaluated as factors associated with early readmission in other studies,3,7,12-14 our current study is the most comprehensive analysis to date. Our analysis considers both cardiac and non-cardiac comorbidities, studying differences in comorbid burden between sexes both in terms of the number of comorbidities and using a global measure of co-morbidity burden (Charlson comorbidity index). Even though comorbidity is not modifiable, better management of comorbid conditions may reduce the risk of readmissions such as the optimization of diabetes control and atrial fibrillation rate control.  This is supported by existing literature suggesting that reasons for readmissions are often not related to index hospitalization but rather comorbidities present at index episode of care and that attention to management of comorbidities in the post-discharge period may circumvent potentially avoidable readmissions.15,16 The translational impact of our results implies that PCI operators need to pay more attention to comorbidities of high-risk patients and closely monitor them after discharge in order to reduce early readmissions.
A key finding of our study is that the causes of readmission after PCI across both sexes appear to be similar, with the majority of unplanned readmissions due to non-cardiac causes.  There are several reasons why our findings deviate from previous literature which suggest that cardiac-related disorders or complications related disorders represent the most common cause of unplanned early readmission.2 Much of the previous literature that has examined causes of readmission is derived from cohorts undergoing PCI 10-20 years ago and therefore does not reflect contemporary clinical practices or PCI technology.  For example, our study is derived from an era in which there is more routine use of physiology such as non-invasive imaging, fractional flow reserve, and intravascular imaging to guide PCI procedures, that have allowed operators to better select lesions that require treatment and better optimize PCI outcomes.  Improvements in stent design using thinner struts may reduce early stent thrombosis rates and early MACE events further.17,18 Newer more powerful antithrombotic agents routinely used in contemporary practice may contribute to reduced thrombotic complications albeit at the expense of non-cardiac bleeding complications.  
Targeted interventions are needed to reduce readmissions after PCI, with the greatest unmet need in women.  One previous study tested an intervention which involved initial patient readmission risk assessment and used a discharge checklist to ensure access to appropriate medications and close follow-up of high risk patients which resulted in a reduction of 30 day readmissions after PCI from 9.6% to 5.3%.19  The evidence from the current study that comorbidities are a strong predictor of readmission suggests that better management of comorbidities may reduce readmissions.  This is supported by a previous study which found that potentially avoidable readmissions were usually possible complications of an underlying comorbidity and post-discharge care should focus attention on comorbidities patients have.20 However, an intervention involving better management of comorbidity has yet to be tested in the context of PCI patients and may be an area for future studies.
Our study has several strengths.  First, this is the first sex specific study of 30-day readmissions after PCI and is a large national study of incidence, predictors, causes and costs of readmissions. Secondly, we included 2 year data from a national perspective while the most recent study of readmissions reviewed patients after acute myocardial infarction and only reported finding from 1-year data.21 In addition, compared to existing studies we were able to evaluate more patient variables and provide a detailed and comprehensive evaluation of comorbidities.  Finally, our dataset is largely complete and we did not have issues of missing data. Our study is also subject to limitations of retrospective analyses of administrative data. Our data was collected from administrative claims sampled from 21 states, which account for 49% of the US population and hospitalizations but the results of the current study may not be generalizable to all regions as geographic heterogeneity in outcomes could not be explored.22 Secondly, the overall data is comprised of 2 unique datasets corresponding to each in the period between 2013 to 2014 and no linkage is possible between years. Thirdly, the dataset does not capture data particularly around pharmacotherapy, angiographic and procedural characteristics of the cohorts undergoing PCI and differences between groups may contribute in part to some of the findings reported. Fourthly, as with any such administrative database, coding errors are always a potential source of bias as is underreporting of secondary and co-morbid diagnosis. Finally, causes of readmission were identified using the primary discharge diagnosis codes which may be subject to reporting biases, although previous studies have used a similar approach for transcatheter aortic valve replacement readmissions.23,24
In conclusion, in our analysis of over 800,000 PCI procedures undertaken over a 2 year period, we report that 1 in 10 women who undergo PCI are readmitted within 30 days. Even once differences in clinical characteristics and outcomes across sexes for the index admission are adjusted for, the risk of readmission in women is 19% greater than that for men. We observe that across both sexes, the most common causes of readmission are non-cardiac issues, and outcomes of the unplanned readmission are largely similar across sexes. Targeted interventions are needed to reduce readmissions particularly amongst women who represent a high-risk group.
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Table 1: Baseline characteristics and in-hospital outcomes from index admission for percutaneous coronary intervention patients according to readmission status and sex


























Known coronary artery disease	93.2%	92.3%	<0.001	93.7%	92.0%	<0.001
Previous myocardial infarction	15.2%	12.6%	<0.001	17.7%	13.7%	<0.001
Previous percutaneous coronary intervention	21.6%	19.3%	<0.001	23.6%	20.0%	<0.001
Previous coronary artery bypass graft	7.8%	6.1%	<0.001	10.2%	7.3%	<0.001
Previous valve disease	0.4%	0.7%	<0.001	0.8%	0.9%	0.15
Atrial fibrillation	11.6%	12.5%	<0.001	19.5%	19.5%	0.92











































Emergency coronary artery bypass graft	1.6%	1.1%	<0.001	1.8%	1.1%	<0.001
Length of stay, days	3.7±5.4	4.3±6.0	<0.001	4.5±3.9	4.9±4.0	<0.001





Transfer to other institution	3.5%	7.3%		7.3%	11.4%	
Care home	5.7%	10.6%		12.0%	17.3%	





Table 2: Independent predictors of 30-day unplanned readmissions after percutaneous coronary intervention for men and women

Predictors	Men	Women
	Odds ratio (95% CI)	P-value	Odds ratio (95% CI)	P-value
Elective	0.732 (0.677-0.791)	<0.001	0.737 (0.685-0.793)	<0.001
Diagnosis of acute myocardial infarction	0.805 (0.764-0.847)	<0.001	1.035 (0.990-1.081)	0.13
Primary expected payer compared to MedicareMedicaidPrivateUninsuredNo charge	1.077 (0.979-1.185)0.598 (0.558-0.641)0.624 (0.552-0.705)0.774 (0.611-0.980)	0.13<0.001<0.0010.033	1.111 (1.026-1.204)0.737 (0.689-0.789)0.720 (0.636-0.815)0.911 (0.719-1.154)	0.010<0.001<0.0010.44
Smoker	0.977 (0.935-1.021)	0.31	0.942 (0.901-0.985)	0.009





Atrial fibrillation	1.293 (1.220-1.370)	<0.001	1.413 (1.338-1.493)	<0.001
Previous transient ischemic attack/stroke	1.189 (1.108-1.275)	<0.001	1.157 (1.079-1.241)	<0.001
Peripheral vascular disease	1.186 (1.116-1.261)	<0.001	1.340 (1.073-1.212)	<0.001
Chronic lung disease	1.453 (1.378-1.532)	<0.001	1.323 (1.261-1.389)	<0.001
Renal failure	1.452 (1.372-1.537)	<0.001	1.452 (1.374-1.535)	<0.001
Liver disease	1.655 (1.440-1.903)	<0.001	1.269 (1.080-1.491)	0.004





Fractional flow reserve	1.123 (0.977-1.291)	0.103	1.172 (1.044-1.315)	0.007
Drug eluting stent	0.803 (0.763-0.844)	<0.001	0.815 (0.776-0.856)	<0.001
Transient ischemic attack/stroke	0.92 (0.854-1.094)	0.66	0.846 (0.761-0.940)	0.002
Index percutaneous coronary intervention length of stay	0.975 (0.971-0.980)	<0.001	0.978 (0.974-0.982)	<0.001
Discharge location vs home (self-care)Short term hospitalTransfer to other institutionCare homeLeft against medical advice or discontinue care	1.310 (1.000-1.717)1.838 (1.673-2.020)1.762 (1.634-1.899)1.664 (1.312-2.111)	0.050<0.001<0.001<0.001	1.471 (1.145-1.890)1.369 (1.260-1.488)1.540 (1.452-1.633)1.956 (1.429-2.679)	0.003<0.001<0.001<0.001
Comorbidities
Charlson score	1.320 (1.304-1.336)	<0.001	1.228 (1.213-1.243)	<0.001




Table 3: Causes of readmission for men and women





B) Specific causes of non-cardiac readmissions for men and women
Men	 	 	 	Women	 	 	 






Peripheral vascular disease	4.30	%	Renal failure	4.50	%




C) Specific causes of cardiac readmissions for men and women
Men	 	 	 	Women	 	 	 
CAD including angina	33.47	%	Heart failure	29.64	%
Acute myocardial infarction	22.50	%	CAD including angina	28.54	%


















Supplementary Table 1: Classification of Clinic Classification Softward codes for Readmissions Causes
Causes of readmission	CCS code	Diagnosis
Respiratory	127	Chronic obstructive pulmonary disease and bronchietasis
	128	Asthma
	130	Pleurisy, pneumothorax, pulmonary collapse
	131	Respiratory failure, insufficiency and arrest
	132	Lung disease due to external agents
	133	Other lower respiratory disease













	78	Other CNS infection and poliomyelitis
	90	Inflammation or infection of eye
	122	Pneumonia
	123	Influenza
	124	Acute and chronic tonsillitis
	125	Acute bronchitis
	126	Other upper respiratory infections
	129	Aspiration pneumonitis
	135	Intestinal infection
	197	Skin and subcutaneous tissue infections
	201	Infective arthritis and osteomyelitis (except that caused by tuberculosis or sexually transmitted disease)
Bleeding 	60	Acute posthemorrhagic anemia
	153	Gastrointestinal hemorrhage
	182	Hemorrhage during pregnancy; abrutio placenta; placenta previa
Peripheral vascular disease 	114	Peripheral and visceral atherosclerosis
	115	Aortic, peripheral and visceral artery aneurysms
	116	Aortic and peripheral arterial embolism or thrombosis
	117	Other circulatory disease
	118	Phlebitis, thrombophlebitis and thromboembolism
	119	Varicose veins of lower extremities
Genitourinary 	159	Urinary tract infection
	160	Calculus of the urinary tract
	161	Other diseases of kidney and ureters
	162	Other diseases of bladder and urethra
	163	Genitourinary symptoms and ill-defined conditions
	164	Hyperplasia of prostate
	165	Inflammatory conditions of the male genital organs
	166	Other male genital disorders
	170	Prolapse of female genital organs
	175	Other female genital disorders
	215	Genitourinary congenital anomalies
Renal disease	156	Nephritis; nephrosis; renal sclerosis
	157	Acute and unspecified renal failure
	158	Chronic kidney disease
Gastrointestinal 	138	Esophageal disorders
	139	Gastroduodenal ulcer (except hemorrhage)
	140	Gastritis and duodenitis
	141	Other disorders of stomach and duodenum
	142	Appendicitis and other appendiceal conditions
	143	Abdominal hernia
	144	Regional enteritis and ulcerative colitis
	145	Intestinal obstruction without hernia
	146	Diverticulosis and diverticulitis
	147	Anal and rectal conditions












	110	Occlusion of stenosis of precerebral arteries
	111	Other and ill-defined cerebrovascular disease
	112	Transient cerebral ischemia
	113	Late effects of cerebrovascular disease
Trauma	207	Pathological fracture
	225	Joint disorders and dislocations; trauma-related
	226	Fracture of neck of femur (hip)
	227	Spinal cord injury
	228	Skull and face fractures
	229	Fracture of upper limb




	234	Crushing injury or internal injury
	235	Open wounds of head; neck; and trunk
	236	Open wounds of extremities
	239	Superficial injury; contusion
	244	Other injuries and conditions due to external causes
	260	All (external causes of injury and poisoning)
Endocrine/metabolic	48	Thyroid disorders
	49	Diabetes mellitus without complication
	50	Diabetes mellitus with complication
	51	Other endocrine disorders
	53	Disorders of lipid metabolism
	58	Other nutritional and endocrine/metabolic disorders
	186	Diabetes or abnormal glucose tolerance complicating pregnancy; childbirth; or the puerperium
Neuropsychiatric 	650	Adjustment disorders
	651	Anxiety disorders
	652	Attention-deficit, conduct, and disruptive behavior disorders
	653	Delirium, dementia, and amnestic and other cognitive disorders
	654	Developmental disorders
	655	Disorders usually diagnosed in infancy and childhood or adolescence
	656	Impulse control disorders, NEC
	657	Mood disorders
	658	Personality disorders
	659	Schizophrenia and other psychotic disorders
	660	Alcohol-related disorders
	661	Substance-related disorders
	662	Suicide and intentional self-inflicted injury
	663	Screening and history of mental health and substance abuse codes
	670	Miscellaneous mental health disorders
	79	Parkinson's disease
	80	Multiple sclerosis




	85	Coma, stupor and brain damage
	95	Other nervous system disorders
	216	Nervous system congenital anomalies
	650	Adjustment disorders
	651	Anxiety disorders
	652	Attention-deficit, conduct, and disruptive behavior disorders
	653	Delirium, dementia, and amnestic and other cognitive disorders
	654	Developmental disorders




	659	Schizophrenia and other psychotic disorders
	660	Alcohol-related disorders
	661	Substance-related disorders
	662	Suicide and intentional self-inflicted injury
	663	Screening and history of mental health and substance abuse codes
	670	Miscellaneous mental health disorders




	15	Cancer of rectum and anus
	16	Cancer of liver and intrahepatic bile ducts
	17	Cancer of pancreas
	18	Cancer of other gastrointestinal organs, peritoneum
	19	Cancer of bronchus, lung
	20	Cancer of other respiratory and intrathoracic
	21	Cancer of bone and connective tissue
	22	Melanoma of skin





	28	Cancer of other female genital organs
	29	Cancer of prostate
	30	Cancer of testis
	31	Cancer of other male genital organs
	32	Cancer of bladder
	33	Cancer of kidney and renal pelvis
	34	Cancer of other urinary organs






	41	Cancer, other and unspecified primary
	42	Secondary malignancies
	43	Malignant neoplasm without specification of site
	44	Neoplasm of unspecified nature or uncertain behavior
	46	Benign neoplasm of uterus
	47	Other and unspecified benign neoplasm
	59	Deficiency and other anemias
	61	 Sickle cell anemia
	62	Coagulation and hemorrhagic disorders
	63	Disease of white blood cells
	64	Other hematologic conditions
Rheumatology problem	54	Gout and other crystal arthropathies
Opthalmology problem	86	Cataract
	87	Retinal detachment defects, vascular occlusion and retinopathy
	88	Glaucoma
	89	Blindness and vision defects
	91	Other eye disorders
ENT problem	92	Otitis media and related conditions
	93	Conditions associate with dizziness or vertigo
	94	Other ear and sense organ disorder
Non-specific chest pain	102	Non-specific chest pain
Oral health problem	136	Disorders of teeth and jaw
	137	Diseases of mouth; excluding dental
Obstetric admission including pregnancy	174	Female infertility





	181	Other complications of pregnancy





	190	Fetal distress and abnormal forces of labor
	191	Polyhydramnios and other problems of amniotic cavity
	192	Umbilical cord complication
	193	OB-related trauma to perineum and vulva
	194	Forceps delivery
	195	Other complications of birth; puerperium affecting management of mother
	196	Other pregnancy and deliver including normal
	218	Liveborn
	219	Short gestation; low birth weight; and fetal growth retardation
	220	Intrauterine hypoxia and birth asphyxia
	223	Birth trauma
	224	Other perinatal conditions
Dermatology problem	198	Other inflammatory condition of skin
	199	Chronic ulcer of skin
	200	Other skin disorders
Poisoning	241	Poisoning by psychotrophic agents
	242	Poisoning by other medication and drugs
	243	Poisoning by nonmedical substances
Syncope	245	Syncope
Other non-cardiac 	10	Immunization and screening for infectious disease
	45	Maintenance chemotherapy, radiotherapy
	52	Nutritional deficiencies




	121	Other diseases of veins and lymphatics
	167	Nonmalignant breast conditions




	202	Rheumatoid arthritis and related disease
	203	Osteoarthritis
	204	Other non-traumatic joint disorders




	210	Systemic lupus erythematosus and connective tissue disorders
	211	Other connective tissue disease
	212	Other bone disease and musculoskeletal deformities
	217	Other congenital anomalies
	237	Complication of device; implant or graft
	238	Complications of surgical procedure or medical care
	240	Burns









	258	Other screening for suspected conditions (not mental disorders or infectious disease)
	259	Residual codes; unclassified
Heart failure 	108	Congestive heart failure non-hypertensive
Arrhythmia 	106	Cardiac dysrhythmias
	107	Cardiac arrest and ventricular fibrillation
Conduction disorder 	105	Conduction disorders
Valve disorders 	96	Heart valve disorder
Hyper/hypotension 	98	Essential hypertension
	99	Hypertension with complications and secondary hypertension
	183	Hypertension complicating pregnancy; childbirth and the puerperium
	249	Shock
Pericarditis 	97	Peri-, endo- and myocarditis, cardiomyopathy
Coronary artery disease including angina	101	Coronary atherosclerosis and other heart disease includes angina
Acute myocardial infarction  	100	Acute myocardial infarction
Others (cardiac)  	103	Pulmonary heart disease
	104	Other and ill-defined heart disease






























Known coronary artery disease	93.3%	92.3%	<0.001
Previous myocardial infarction	15.4%	12.7%	<0.001
Previous percutaneous coronary intervention	21.7%	19.4%	<0.001
Previous coronary artery bypass graft	8.0%	6.3%	<0.001
Previous valve disease	0.4%	0.7%	<0.001
Atrial fibrillation	12.3%	13.3%	<0.001












































Emergency coronary artery bypass graft	1.6%	1.1%	<0.001
Length of stay, days	3.7±5.3	4.4±5.8	<0.001





Transfer to other institution	3.8%	7.8%	
Care home	6.2%	11.3%	
Left against medical advice or discontinue care	0.6%	0.3%	
Destination unknown	0.02%	0.02%	
Readmission within 30 days
Rate of readmissions	8.4%	11.5%	<0.001






